Registered outcomes15

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 15 of 15

List	Outcome	Time frame	Description
Primary	One-month Mortality Rate Between the Two Arms	One-month	1-month mortality is defined as the proportion of patients who met fatal outcome event by Day 30
Primary	Lung Function Assessment - Proportion of the Patients With Stable or Improved SpO2 Without Increasing FiO2	Day 7, Day 14, Day 21 & Day 30	Stable SpO2: Defined as number of patients with absence of increase in FiO2 to maintain SpO2 ≥ 92% Improvement of SpO2: Defined as number of patients with decrease in FiO2 to maintain SpO2 \> 92%
Primary	Endo-tracheal Intubation/Invasive Mechanical Ventilation (IMV)	Day 30	Number of patients needing Intubation/IMV post treatment
Primary	Reduction in Proportion of Patients on Non-invasive Ventilation	Baseline (Day 1), Day 7, Day 14 Day 21 & Day 30	Reduction in proportion of Patients on Non-invasive Ventilation: defined as number of patient improved and shifted to Face mask, Nasal cannula, non-rebreather mask or off oxygen over time
Primary	Lung Function Assessment - Proportion of Patients With Stable PaO2 Without Increasing FiO2	Day 7, Day14, Day 21 & Day30	Stable PaO2: Defined as number of patients with up to 10% change in PaO2/FiO2 ratio from baseline. Improvement of PaO2: Defined as number of patients with \> 10% improvement in PaO2/FiO2 ratio from baseline (including patients weaned off oxygen).
Primary	Reduction in Proportion of Patients- Invasive Mechanical Ventilation	Day7, Day14, Day21 & Day 30	Patient improved from invasive ventilation over time from baseline.
Primary	Reduction in Proportion of Patients-High Flow Nasal Oxygen	Day7 ,Day 14 ,Day 21, Day 30	Patient improved from High Flow Nasal Oxygen over time from baseline.
Primary	Mean Change From Baseline in Ferritin	Day 7, Day 14, Day 21 & Day 30	Mean Change from Baseline in Ferritin
Primary	Mean Change From Baseline in LDH	Day 7, Day14, Day 21 and Day 30.	Mean Change from Baseline in LDH
Primary	Mean Change From Baseline in CRP (C-reactive Protein)	Day 7, Day 14, Day 21 & Day 30	Mean Change from Baseline in CRP
Primary	Mean Change From Baseline D-Dimer	Day 7, Day 14, Day 21 & Day 30
Secondary	Mean Change From Baseline of Absolute Lymphocyte Count	day 7, day 14 ,day 21 & day 30	Mean change From baseline in Lymphocyte count
Secondary	Biomarkers (IL-6, TNF-a)	Pre and Post 1st dose; Pre and Post 2nd dose	Mean values of Pre and Post 1st and 2nd dose are shown
Secondary	Mean PaO2 (Partial Pressure of Oxygen) / FiO2 (Fraction of Inspired Oxygen, FiO2) Ratio (or P/F Ratio)	Baseline, Day 7, Day 14, Day 21 & Day 30	Mean PaO2 (partial pressure of oxygen) / FiO2 (fraction of inspired oxygen, FiO2) ratio (or P/F ratio)
Secondary	Number and Percentage of Patients With Radiological Response	up to Day 30	Number of patients with improved X ray/CT findings as compared to baseline or returned to normal in the last assessment

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04475588/registered

API reference For AI assistants